Effect of Intravenous FerRic carbOxymaltose oN Reverse Remodeling Following Cardiac Resynchronization Therapy
Status:
Completed
Trial end date:
2021-08-04
Target enrollment:
Participant gender:
Summary
To assess impact on left ventricular reverse remodeling defined as a change in left
ventricular ejection fraction in heart failure patients with reduced ejection fraction (and
previous implantation of cardiac resynchronization therapy) undergoing treatment with ferric
carboxymaltose vs. placebo